Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxoprexin in metastatic hormone-refractory prostate cancer
NCT00024414Phase 2Unknown
- Sponsor
- Theradex Oncology
- Start
- Apr 2001
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel docosahexaenoic acid in prostate cancer (PCa), sponsored by Theradex Oncology. Status: unknown.
02
Drugs
paclitaxel docosahexaenoic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00024414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024414.